BA
PRTK

BlackRock Advisors’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

BlackRock Advisors’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$142K Sell
9,218
-584
-6% -$7.58K ﹤0.01% 2883
2016
Q3 		$128K Buy
9,802
+4,545
+86% +$60.3K ﹤0.01% 2913
2016
Q2 		$73K Buy
5,257
+996
+23% +$14.7K ﹤0.01% 3104
2016
Q1 		$65K Buy
4,261
+362
+9% +$5.54K ﹤0.01% 3094
2015
Q4 		$74K Sell
3,899
-2,658
-41% -$50.7K ﹤0.01% 3059
2015
Q3 		$125K Sell
6,557
-5,101
-44% -$127K ﹤0.01% 2993
2015
Q2 		$300K Buy
11,658
+10,559
+961% +$300K ﹤0.01% 2547
2015
Q1 		$34K Hold
1,099
– – ﹤0.01% 3335
2014
Q4 		$42K Sell
1,099
-254
-19% -$6.07K ﹤0.01% 3320
2014
Q3 		$33K Buy
1,353
+526
+64% +$13.7K ﹤0.01% 3378
2014
Q2 		$20K Buy
827
+293
+55% +$9.55K ﹤0.01% 3453
2014
Q1 		$20K Buy
534
+260
+95% +$10.3K ﹤0.01% 3420
2013
Q4 		$11K Hold
274
– – ﹤0.01% 3500
2013
Q3 		$10K Sell
274
-189
-41% -$6.77K ﹤0.01% 3465
2013
Q2 		$17K Buy
+463
New +$19.8K ﹤0.01% 3303

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

BlackRock Advisors's PRTK Position: Q4 2016 in Review

BlackRock Advisors reduced its Paratek Pharmaceuticals, Inc. (PRTK) stake by 6% in Q4 2016, selling an estimated $7.58K and leaving 9,218 shares worth $142K. The position accounts for ﹤0.01% of the portfolio, ranked #2883.

BlackRock Advisors first reported a position in PRTK in Q2 2013 and has held it in 15 quarters since. The position peaked at $300K in Q2 2015. 92 funds tracked by Wall St. Rank hold PRTK as of Q4 2016.

  • BlackRock Advisors held 9,218 shares of Paratek Pharmaceuticals, Inc. worth $142K as of Q4 2016.
  • BlackRock Advisors sold 584 Paratek Pharmaceuticals, Inc. shares in Q4 2016, an estimated $7.58K.
  • Paratek Pharmaceuticals, Inc. made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #2883 holding.
  • BlackRock Advisors first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Advisors's Paratek Pharmaceuticals, Inc. position peaked at $300K in Q2 2015.
  • 92 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.